Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

J&J is already seeing strong sales growth for its treatment-resistant depression (TRD) and MDD therapy Spravato (esketamine), ...

Among 347,468 individuals who had lived with persistent pain for over 3 months, clinical symptoms of depression and anxiety ...

Depression and anxiety affect approximately 40% of adults with chronic pain, according to a massive new systematic review and meta-analysis published in JAMA Network Open. The comprehensive study ...

A large-scale study published in Molecular Psychiatry has uncovered a distinct pattern of biological changes in people with ...

Johnson & Johnson JNJ decided to discontinue the Phase 3 VENTURA development program, which is evaluating aticaprant as an ...

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

Learn the difference between having unipolar and bipolar depression and what mental health conditions they are categorized ...

Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion ...

The latest health news includes Johnson & Johnson halting testing on a depression drug, USDA eliminating food safety advisory ...

Major depressive disorder with seasonal patterns, also known as seasonal affective disorder, causes symptoms similar to ...

Discover the complexities of postpartum depression, its causes, and effective support strategies for new mothers.